Synergistic effect of endothelin-1 and cyclic AMP on glucose transport in 3T3-L1 adipocytes.
We have demonstrated previously that chronic exposure to endothlin-1 enhances glucose transport in 3T3-L1 adipocytes via augmented GLUT1 mRNA and protein accumulation. In the present study, we further examined the combined effect of endothelin-1 (ET-1) and cAMP on glucose transport. In cells pretreated with ET-1 and 8-bromo cAMP for 8 h, a synergy between these two agents on glucose uptake was found. Insulin-stimulated glucose transport, on the other hand, was only slightly affected. The synergistic effect of these two agents was suppressed in the presence of cycloheximide and actinomycin D. Immunoblot and Northern blot analyses revealed that GLUT1 protein and mRNA levels were both increased in cells pretreated with both ET-1 and 8-bromo cAMP, greater than the additive effect of each agent alone. Further examination demonstrated that the stability of GLUT1 mRNA was markedly enhanced in the presence of both ET-1 and cAMP. To investigate the transcriptional activation of Glut1 gene, transient transfection of cells with luciferase reporter construct driven by Glut1 promoter was performed. We found that Glut1 transcription was also increased by ET-1 and cAMP in a synergistic fashion. In addition, similar synergy between ET-1 and beta-adrenergic agonists on glucose transport was found. The synergistic action of ET-1 with 8-bromo cAMP to enhance glucose transport was inhibited by GF109203X, a selective protein kinase C (PKC) inhibitor, and was mimicked by 4beta-phorbol 12beta-myristate 13alpha-acetate (PMA), a PKC activator. Furthermore, PMA was found to act synergistically with 8-bromo cAMP to induce Glut1 transcription and ET-1 was shown to activate novel PKCdelta and PKC. Taken together, these results indicate that ET-1 may act with cAMP in a synergistic way to increase glucose transport, probably through enhanced GLUT1 expression via a PKC-dependent mechanism.
Fong
Jim C
JC
Institute of Biochemistry, National Yang-Ming University, 155, Sec. 2, Linung Street, 112 Taipei, Taiwan. ffong@ym.edu.tw
Kao
Ying-Shiun
YS
Tsai
Hui-Ying
HY
Chiou
Yu-Ya
YY
Chiou
Guang-Yu
GY
D041721:3T3-L1 Cells; D015124:8-Bromo Cyclic Adenosine Monophosphate / Q000378:metabolism; D017667:Adipocytes / Q000378:metabolism*; D000818:Animals; D001692:Biological Transport; D015152:Blotting, Northern; D002462:Cell Membrane / Q000378:metabolism; D000242:Cyclic AMP / Q000378:metabolism*; D003600:Cytosol / Q000378:metabolism; D018076:DNA, Complementary / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D019332:Endothelin-1 / Q000378:metabolism*; D005947:Glucose / Q000378:metabolism*; D015151:Immunoblotting; D008156:Luciferases / Q000378:metabolism; D051379:Mice; D020033:Protein Isoforms; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000737:chemistry; D012313:RNA / Q000378:metabolism; D013997:Time Factors; D014162:Transfection
D018076:DNA, Complementary; D019332:Endothelin-1; D020033:Protein Isoforms; D015124:8-Bromo Cyclic Adenosine Monophosphate; D012313:RNA; D000242:Cyclic AMP; D008156:Luciferases; D011493:Protein Kinase C; D005947:Glucose